1. Department of Safety, Pharmaceutical Affairs Bureau, Japanese Ministry of Health & Welfare (1989) Administration of high-dose medroxyprogesterone acetate and severe thrombosis (in Japanese). Iyakuhin Fukusayo John No. 96, 1
2. Japanese Breast Cancer Society (1992) Standards for assessment of the therapeutic effects in advanced or recurrent breast cancer patients (in Japanese). In: General rules for clinical and pathological recording of breast cancer. Kanehara Shuppan, Tokyo, pp 53?61
3. Japan Society for Cancer Therapy (1986) Criteria for the evaluation of the clinical effects of solid cancer chemotherapy (in Japanese). Nippon Gann Chiryou Gakkaishi (J Jpn Soc Cancer Ther) 21:931?942
4. Tominaga T, Izuo M, Nomura Y, Kubo K, Abe O, Enomoto K, Takatani O (1982) Oral high-dose medroxyprogesterone acetate (MPA) in the treatment of advanced and recurrent breast cancer: A dose response evaluartion (in Japanese with English abstract). Gan To Kagakuryoho (Jpn J Cancer Chemother) 9:1994?2004
5. Yoshida M, Murai H, Miura S (1985) Therapeutic effects of medroxyprogresterone acetate in recurrent or advanced breast cancer (in Japanese with English abstract). Gan To Kagakuryoho (Jpn J Cancer Chemother) 12:516?523